Marshall Wace
URGN icon

Marshall Wace’s UroGen Pharma URGN Stock Holding History

Marshall Wace’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,300
Closed -$382K – 3705
2025
Q4 		$382K Sell
16,300
-2,375
-13% -$51.5K ﹤0.01% 2358
2025
Q3 		$373K Sell
18,675
-1,985
-10% -$35.6K ﹤0.01% 2346
2025
Q2 		$283K Buy
20,660
+9,160
+80% +$87.9K ﹤0.01% 2344
2025
Q1 		$127K Sell
11,500
-124,991
-92% -$1.33M ﹤0.01% 2473
2024
Q4 		$1.45M Buy
+136,491
New +$1.63M ﹤0.01% 1565
2024
Q3 		– Sell
-42,841
Closed -$719K – 2978
2024
Q2 		$719K Buy
+42,841
New +$609K ﹤0.01% 1818
2024
Q1 		– Sell
-28,552
Closed -$428K – 2823
2023
Q4 		$428K Buy
28,552
+1,731
+6% +$22.5K ﹤0.01% 1769
2023
Q3 		$376K Sell
26,821
-60,059
-69% -$964K ﹤0.01% 1805
2023
Q2 		$899K Buy
86,880
+71,572
+468% +$790K ﹤0.01% 1763
2023
Q1 		$141K Buy
+15,308
New +$141K ﹤0.01% 2453
2020
Q1 		– Sell
-1,769
Closed -$59K – 2076
2019
Q4 		$59K Buy
1,769
+550
+45% +$15K ﹤0.01% 1527
2019
Q3 		$29K Buy
+1,219
New +$39.9K ﹤0.01% 1573

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Marshall Wace's URGN Position: Q1 2026 in Review

Marshall Wace sold out of UroGen Pharma (URGN) in Q1 2026, closing a stake of 16,300 shares — an estimated $382K sold.

Marshall Wace first reported a position in URGN in Q3 2019 and held it in 12 quarters. The position peaked at $1.45M in Q4 2024. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • Marshall Wace reported no remaining UroGen Pharma position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 16,300 UroGen Pharma shares in Q1 2026, an estimated $382K.
  • Marshall Wace first reported a position in UroGen Pharma in Q3 2019 and held it in 12 quarters.
  • Marshall Wace's UroGen Pharma position peaked at $1.45M in Q4 2024.
  • 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.